We would love to hear your thoughts about our site and services, please take our survey here.
BNN Breaking is a news website based in Hong Kong launched in 2022 by Indian-American entrepreneur Gurbaksh Chahal. It has been criticised for posting a number of misleading and inaccurate news stories, potentially using AI-driven content aggregation.
That’s actually a weakness, not a strength.
“So, I'm basically cheesed off with myself that a mischief- maker like Fastfood is having an effect; and that's due to my lack of personal power/ information - down to me.”
Good for you for wanting to dig deeper but I wouldn’t concern yourself with fastfood’s cryptic comments.
Apart from getting it from the horses mouth, there is only one other way that he would know who’s selling, but not recently as there are time limits.
Also, if he did know, he’d have said so by now.
Tech, the Company won’t be able to answer your question. (Even in the unlikely event that a significant shareholder has told them they are selling)
As has been previously mentioned, the Company has a duty to keep their significant shareholder list up to date, but they can only rely on the shareholder notifying the Company. No notifications = no change.
Hi fastfood,
Back in early January you said that you had a bit to say on Ciz, but would hold out till Feb/March.
It’s now March.
The 2 year chart on that share looks like something only Eddie The Eagle would enjoy.
Only just joined the dots myself Tech.
Last post anywhere, 13th Feb.
If we’ll get a trade reported today?🤔
“ I khave a bit to say on Ciz but will hold off until FEB/March as do not want to tempt fate. I will at the time refer back to this Post to see if my Positive belief held up. So I shall say Q2 will or can show significant step change. GLA to all holders. “
Buy Price today 2.69.
Thanks Jace, but I can only read the opening paragraph as the rest of the article is behind a pay wall.
V
I don’t recall reading that article.
Does anyone have a link?
Cheers
VV
We’ll see later on today if those buys on Friday we’re Helikon reducing further.
Tony… another one added to the green coffin crew.
This is PFC, not Narcissist Central.
Nice 900k buy.
Was that you again neilin?
That 100k was my final top up.
I can’t wait to hear what @alus0001 has to say.
Getaway, really.
I just thought it interesting that we are not alone in looking to LFTs for early detection.
Im not invested in APTA.
I meant to flag this up on here last week but never got round to doing it.
APTA were on my watchlist until I watched their results webinar last year. That said, I still think it rather interesting that another Company(s) is looking at LFTs to solve the early detection conundrum of a devastating disease…
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer's disease.
This latest phase involves development of an additional Optimer binder against the innovative Neuro-Bio target implicated in Alzheimer's disease, with the goal of developing reagents for a lateral flow test for early disease detection. Following the earlier identification of Optimer binders to this novel Alzheimer's disease biomarker,1 these binders have been characterised for use in lateral flow and biosensor assays.
Common lateral flow test formats require a pair of binders to increase diagnostic test accuracy. To prevent the need for animal-derived antibodies in its Alzheimer's disease diagnostic, Neuro-Bio now requires the development of additional binders to support the lateral flow test format and deliver a wholly Optimer-powered test. As Optimer binders are oligonucleotide-based, rather than protein-based like antibodies, they offer further advantages including scalability of manufacture, improved shelf-life and tuneability benefits that will allow more stable and specific reagents for use in lateral flow tests.
Steve Hull, Chairman of Aptamer Group, said: "We are very pleased to continue our exciting relationship with Neuro-Bio to deliver the specific Optimer binders needed to enable this revolutionary diagnostic for this devastating disease. It is great to work with such enthusiastic partners that understand our Optimer technology's benefits and are actively seeking solutions to overcome the industry's problems with antibodies."
Baroness Susan Greenfield, CEO of Neuro-Bio, said: "At Neuro-Bio we're thrilled at entering this next phase of development with Aptamer Group: the first phase proved productive and very promising. Now, this next stage takes us closer to realising a highly novel and much needed technology for detecting neurodegenerative diseases at a very early stage."
Looks like our emotional shareholder has requested that his posts from last night be removed…again!
We should have a sweep on which username he’ll choose to come back with.😂
VV